3-aminobenzamide has been researched along with Alloxan Diabetes in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hence, dosing will play a critical role in clinical studies assessing the merits of NIC and TAU as diabetes-preventing agents." | 1.36 | Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide. ( Lau-Cam, CA; Pandya, KG; Patel, MR, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, J | 1 |
| Xu, BY | 1 |
| Chen, S | 2 |
| Feng, B | 2 |
| Chakrabarti, S | 2 |
| Pandya, KG | 1 |
| Patel, MR | 1 |
| Lau-Cam, CA | 1 |
| Li, WJ | 2 |
| Oh, SJ | 1 |
| Wang, C | 1 |
| George, B | 1 |
| Li, X | 1 |
| Peng, Y | 1 |
| Zhou, J | 1 |
| Li, B | 1 |
| Wang, H | 1 |
| Zhang, J | 1 |
| Wang, Z | 1 |
| Minchenko, AG | 2 |
| Stevens, MJ | 2 |
| White, L | 1 |
| Abatan, OI | 1 |
| Komjáti, K | 1 |
| Pacher, P | 2 |
| Szabó, C | 3 |
| Obrosova, IG | 2 |
| Frank, RN | 1 |
| Seigel, GM | 1 |
| Zsengeller, Z | 2 |
| Uchigata, Y | 1 |
| Yamamoto, H | 2 |
| Nagai, H | 1 |
| Okamoto, H | 2 |
| Yonemura, Y | 1 |
| Takashima, T | 1 |
| Miwa, K | 1 |
| Miyazaki, I | 1 |
| Otsuka, A | 1 |
| Hanafusa, T | 1 |
| Miyagawa, J | 1 |
| Kono, N | 1 |
| Tarui, S | 1 |
| Flechner, I | 1 |
| Maruta, K | 1 |
| Burkart, V | 1 |
| Kawai, K | 1 |
| Kolb, H | 1 |
| Kiesel, U | 1 |
| Yamada, K | 1 |
| Miyajima, E | 1 |
| Nonaka, K | 1 |
| Masiello, P | 2 |
| Novelli, M | 1 |
| Fierabracci, V | 1 |
| Bergamini, E | 2 |
| Cubeddu, TL | 1 |
| Frosina, G | 1 |
| Xiao, CY | 1 |
| Chen, M | 1 |
15 other studies available for 3-aminobenzamide and Alloxan Diabetes
| Article | Year |
|---|---|
Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications.
Topics: Animals; Base Sequence; Benzamides; Diabetes Complications; Diabetes Mellitus, Experimental; DNA Pri | 2008 |
Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide.
Topics: Animals; Benzamides; Blood Glucose; Catalytic Domain; Cholesterol; Diabetes Mellitus, Experimental; | 2010 |
Diabetic cystopathy is associated with PARP/JNK/mitochondrial apoptotic pathway-mediated bladder apoptosis.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Pr | 2010 |
Genotoxic stress and activation of novel DNA repair enzymes in human endothelial cells and in the retinas and kidneys of streptozotocin diabetic rats.
Topics: Animals; Benzamides; Blotting, Western; Curcumin; Diabetes Mellitus, Experimental; DNA Damage; DNA R | 2012 |
Poly(ADP-ribose) polymerase inhibition improves erectile function by activation of nitric oxide/cyclic guanosine monophosphate pathway in diabetic rats.
Topics: Animals; Benzamides; Blotting, Western; Cyclic GMP; Diabetes Mellitus, Experimental; Male; Nitric Ox | 2012 |
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation.
Topics: Animals; Benzamides; Diabetes Mellitus, Experimental; Endothelin-1; Enzyme Activation; Enzyme Inhibi | 2003 |
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.
Topics: Animals; Benzamides; Cell Hypoxia; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme Inh | 2004 |
Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis.
Topics: Animals; Benzamides; Diabetes Mellitus, Experimental; Glucose; Islets of Langerhans; Male; NAD+ Nucl | 1983 |
Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration.
Topics: Animals; Benzamides; Blood Glucose; Diabetes Mellitus, Experimental; Insulin; Islets of Langerhans; | 1984 |
Nicotinamide and 3-aminobenzamide reduce interferon-gamma-induced class II MHC (HLA-DR and -DP) molecule expression on cultured human endothelial cells and fibroblasts.
Topics: Animals; Benzamides; Cells, Cultured; Diabetes Mellitus, Experimental; Endothelium, Vascular; Fibrob | 1991 |
Effects of radical scavengers on the development of experimental diabetes.
Topics: Aging; Animals; Antioxidants; Azoles; Benzamides; Blood Glucose; Butylated Hydroxyanisole; Cysteamin | 1990 |
Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by niacinamide and 3-aminobenzamide.
Topics: Animals; Benzamides; Biological Factors; Cells, Cultured; Cytokines; Diabetes Mellitus, Experimental | 1990 |
Protection by 3-aminobenzamide and nicotinamide against streptozotocin-induced beta-cell toxicity in vivo and in vitro.
Topics: Animals; Benzamides; Blood Glucose; Diabetes Mellitus, Experimental; In Vitro Techniques; Insulin; I | 1990 |
Protective effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase, against streptozotocin-induced diabetes.
Topics: Animals; Benzamides; Blood Glucose; Diabetes Mellitus, Experimental; Insulin; Insulin Secretion; Isl | 1985 |
Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.
Topics: Animals; Apoptosis Inducing Factor; Cell Nucleus; Diabetes Mellitus, Experimental; Enzyme Activation | 2004 |